The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition

Mitsuo Terada(Nagoya City University), Aki Ito(Akita Red Cross Hospital), Yuichiro Kikawa(Kansai Medical University), Kei Koizumi(Hamamatsu University School of Medicine), Yoichi Naito(National Cancer Center Hospital East), Tatsunori Shimoi(National Cancer Center Hospital East), Mikiya Ishihara(Mie University Hospital), Takashi Yamanaka(Kanagawa Prefectural Hospital Organization), Yukinori Ozaki(The Cancer Institute Hospital), Fumikata Hara(The Cancer Institute Hospital), Rikiya Nakamura(Chiba Cancer Center), Masaya Hattori(Aichi Cancer Center), Minoru Miyashita(Tohoku University), Naoto Kondo, Tetsuhiro Yoshinami(The University of Osaka), Masahiro Takada(Kyoto University), Koji Matsumoto(Hyogo Prefectural Cancer Center), Kazukata Narui(Yokohama City University Medical Center), Shinsuke Sasada(Hiroshima University), Takayuki Iwamoto(Kawasaki Medical School Hospital), Mitsuchika Hosoda(Hokkaido University Hospital), Yuko Takano(Nagoya University Hospital), Takaaki Oba(Shinshu University), Hitomi Sakai(Showa University), Akari Murakami(Ehime University Hospital), Toru Higuchi(Saitama Red Cross Hospital), Junko Tsuchida(Niigata University), Yuko Tanabe(Toranomon Hospital), Tomoko Shigechi(Kyushu University), Emi Tokuda(Fukushima Medical University), Michiko Harao(Jichi Medical University), Shinichiro Kashiwagi(Osaka Metropolitan University), Junichi Mase(Gifu Prefectural General Medical Center), Junichiro Watanabe(Juntendo University), Shigenori E. Nagai(Saitama Cancer Center), Chikako Yamauchi(Shiga Medical Center), Yutaka Yamamoto(Kumamoto University Hospital), Hiroji Iwata(Aichi Cancer Center), Shigehira Saji(Fukushima Medical University), Tatsuya Toyama(Nagoya City University)
Breast Cancer
October 7, 2023
Cited by 58Open Access
Full Text

Abstract

The Japanese Breast Cancer Society (JBCS) Clinical Practice Guidelines for systemic treatment of breast cancer were updated to the 2022 edition through a process started in 2018. The updated guidelines consist of 12 background questions (BQs), 33 clinical questions (CQs), and 20 future research questions (FRQs). Multiple outcomes including efficacy and safety were selected in each CQ, and then quantitative and qualitative systematic reviews were conducted to determine the strength of evidence and strength of recommendation, which was finally determined through a voting process among designated committee members. Here, we describe eight selected CQs as important updates from the previous guidelines, including novel practice-changing updates, and recommendations based on evidence that has emerged specifically from Japanese clinical trials.


Related Papers

No related papers found

Powered by citation graph analysis